How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?

Atherosclerosis. 2019 May:284:218-220. doi: 10.1016/j.atherosclerosis.2019.03.003. Epub 2019 Mar 9.

Author

Mariko Harada-Shiba¹

Affiliation

¹ Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan. Electronic address: mshiba@ncvc.go.jp.

PMID: 30894250
DOI: 10.1016/j.atherosclerosis.2019.03.003

No abstract available

Keywords: Atherosclerotic cardiovascular disease; Familial hypercholesterolemia; Guideline; LDL cholesterol; Residual risk.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anticholesteremic Agents*
Cardiovascular Diseases*
Cholesterol, LDL
Humans
Hyperlipoproteinemia Type II*
Prevalence
Proprotein Convertase 9

Substances

Anticholesteremic Agents
Cholesterol, LDL
Proprotein Convertase 9